Lapatinib
Brand: Tykerb (global)
Anticancer
HER2 / EGFR dual TKI
Pharmacokinetics
| Half-life | 14 hours |
| Tmax | 4 h |
| Protein Binding | 99 % |
| Volume of Distribution | 236 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Take on an empty stomach; strong CYP3A substrate; avoid grapefruit. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Diarrhoea, hepatotoxicity, rash, cardiotoxicity
Contraindications:
Severe liver impairment
Precautions:
Monitor LFTs frequently; cardiac EF monitoring recommended